Innovent Receives NMPA Breakthrough Therapy Designation For IBI363 (PD-1/IL-2Α-Bias Bispecific Antibody Fusion Protein) In Melanoma
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...
The Manila Times3d
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
Medindia3d
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) in Melanoma
PR Newswire SAN FRANCISCO and SUZHOU, China, March 30, 2025 SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...
Morningstar3d
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
It is a PD-1/IL-2 bispecific antibody fusion protein designed ... Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III ...
Frontiers18d
IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade
Isolated unprimed or IL-18-primed NK cells (1.0×10 6 cells) were combined with anti-PD-1 mAb and adoptively i.p. transferred to CT26-bearing mice on days 3, 7, 11, and 15. The survival of CT26-bearing ...